| Heading: |
Life Sciences: Research |
| Question ID: |
1805679 |
| UIN: |
54306 |
| House: |
Commons |
| Date tabled: |
2025-05-22 |
| Asking Member ID: |
4484 |
| Asking Member display name: |
Alan Mak
|
| Asking Member handle: |
AlanMakMP
|
| Asking Member Twitter reference: |
@AlanMakMP
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Science, Innovation and Technology, what assessment he has made of the potential impact of changes in levels of funding for medicines on life sciences research. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-06 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4822 |
| Answering Member display name: |
Feryal Clark
|
| Answering Member handle: |
FeryalClark
|
| Answering Member Twitter reference: |
@FeryalClark
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Secretary of State for Science, Innovation and Technology is working closely with the Department of Health and Social Care on the current Mid Scheme Review for the Voluntary Scheme for branded medicines pricing, access and growth (VPAG) and is aware o... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
216 |
| Answering body name: |
Department for Science, Innovation and Technology |
| Tweeted: |
true |